The Zika virus (ZIKV) epidemic has resulted in congenital abnormalities in fetuses and neonates. Although some cross-reactive dengue virus (DENV)-specific antibodies can enhance ZIKV infection in mice, those recognizing the DENV E-dimer epitope (EDE) can neutralize ZIKV infection in cell culture. We evaluated the therapeutic activity of human monoclonal antibodies to DENV EDE for their ability to control ZIKV infection in the brains, testes, placentas, and fetuses of mice. A single dose of the EDE1-B10 antibody given 3 d after ZIKV infection protected against lethality, reduced ZIKV levels in brains and testes, and preserved sperm counts. In pregnant mice, wild-type or engineered LALA variants of EDE1-B10, which cannot engage Fcg receptors, diminished ZIKV burden in maternal and fetal tissues, and protected against fetal demise. Because neutralizing antibodies to EDE have therapeutic potential against ZIKV, in addition to their established inhibitory effects against DENV, it may be possible to develop therapies that control disease caused by both viruses.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


NCBI Reference Sequence


  1. 1.

    et al. Zika virus: History, emergence, biology, and prospects for control. Antiviral Res. 130, 69–80 (2016).

  2. 2.

    et al. Zika virus infection in pregnant women in Rio de Janeiro. N. Engl. J. Med. 375, 2321–2334 (2016).

  3. 3.

    et al. Analysis of blood from Zika-virus-infected fetuses: a prospective case series. Lancet Infect. Dis. 3099, 26–28 (2017).

  4. 4.

    et al. Birth defects among fetuses and infants of US women with evidence of possible Zika virus infection during pregnancy. J. Am. Med. Assoc. 317, 59–68 (2017).

  5. 5.

    et al. Guillain–Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case–control study. Lancet 387, 1531–1539 (2016).

  6. 6.

    et al. Guillain–Barré Syndrome associated with Zika virus infection in Colombia. N. Engl. J. Med. 375, 1513–1523 (2016).

  7. 7.

    et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe 19, 696–704 (2016).

  8. 8.

    et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108, 717–725 (2002).

  9. 9.

    et al. Broadly neutralizing activity of Zika-virus-immune sera identifies a single viral serotype. Cell Rep. 16, 1485–1491.

  10. 10.

    et al. Structural basis of potent Zika–dengue virus antibody cross-neutralization. Nature 536, 48–53 (2016).

  11. 11.

    et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 16, 170–177 (2015).

  12. 12.

    & Vaccination strategies against Zika virus. Curr. Opin. Virol. 23, 59–67 (2017).

  13. 13.

    et al. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4, e1000060 (2008).

  14. 14.

    et al. Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections. JCI Insight 2, (2017).

  15. 15.

    , , , & Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect. Dis. 10, 712–722 (2010).

  16. 16.

    et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat. Immunol. 17, 1102–1108 (2016).

  17. 17.

    et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823–826 (2016).

  18. 18.

    et al. Structural basis of Zika-virus-specific antibody protection. Cell 166, 1016–1027 (2016).

  19. 19.

    et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540, 443–447 (2016).

  20. 20.

    et al. Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico. Cell 169, 597–609 (2017).

  21. 21.

    et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci. Transl. Med. 8, 369ra179 (2016).

  22. 22.

    et al. Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against Zika virus. MBio 7, e01123–e16 (2016).

  23. 23.

    et al. Zika virus infection of rhesus macaques leads to viral persistence in multiple tissues. PLoS Pathog. 13, e1006219 (2017).

  24. 24.

    et al. Zika Virus infection in mice causes panuveitis with shedding of virus in tears. Cell Rep. 16, 3208–3218 (2016).

  25. 25.

    et al. Zika virus RNA replication and persistence in brain and placental tissue. Emerg. Infect. Dis. 23, 405–414 (2017).

  26. 26.

    et al. Zika virus persistence in the central nervous system and lymph nodes of rhesus monkeys. Cell 169, 610–620 (2017).

  27. 27.

    et al. Zika virus infection damages the testes in mice. Nature 540, 438–442 (2016).

  28. 28.

    et al. Zika virus causes testis damage and leads to male infertility in mice. Cell 167, 1511–1524 (2016).

  29. 29.

    et al. Vaginal exposure to Zika virus during pregnancy leads to fetal brain infection. Cell 166, 1247–1256 (2016).

  30. 30.

    et al. Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. Nat. Commun. 8, 15411 (2017).

  31. 31.

    & A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection. Prog. Mol. Biol. Transl. Sci. 129, 141–166 (2015).

  32. 32.

    et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101–104 (2007).

  33. 33.

    , , & Therapeutic antibodies in ophthalmology: old is new again. MAbs 2, 176–180 (2010).

  34. 34.

    et al. Zika virus infection during pregnancy in mice causes placental damage and fetal demise. Cell 165, 1081–1091 (2016).

  35. 35.

    et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature 534, 267–271 (2016).

  36. 36.

    et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg. Infect. Dis. 17, 880–882 (2011).

  37. 37.

    et al. Potential sexual transmission of Zika virus. Emerg. Infect. Dis. 21, 359–361 (2015).

  38. 38.

    et al. Male-to-female sexual transmission of Zika virus—United States, January–April 2016. Clin. Infect. Dis. 64, 211–213 (2017).

  39. 39.

    , , , & Suspected female-to-male sexual transmission of Zika virus—New York City, 2016. MMWR Morb. Mortal. Wkly. Rep. 65, 716–717 (2016).

  40. 40.

    et al. Male-to-male sexual transmission of Zika virus—Texas, January 2016. MMWR Morb. Mortal. Wkly. Rep. 65, 372–374 (2016).

  41. 41.

    et al. Infection dynamics in a traveller with persistent shedding of Zika virus RNA in semen for six months after returning from Haiti to Italy, January 2016. Euro Surveill. 21, 30316 (2016).

  42. 42.

    et al. Vaccine-mediated protection against Zika-virus-induced congenital disease. Cell 170, 273–283 (2017).

  43. 43.

    et al. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J. Virol. 87, 8826–8842 (2013).

  44. 44.

    et al. Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen? Lancet Infect. Dis. 16, 405 (2016).

  45. 45.

    et al. Prolonged detection of Zika virus in vaginal secretions and whole blood. Emerg. Infect. Dis. 23, 99–101 (2017).

  46. 46.

    et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc. Natl. Acad. Sci. USA 108, 20690–20694 (2011).

  47. 47.

    , , & Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat. Med. 20, 143–151 (2014).

  48. 48.

    et al. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc. Natl. Acad. Sci. USA 111, 5992–5997 (2014).

  49. 49.

    et al. Zika virus preferentially replicates in the female reproductive tract after vaginal inoculation of rhesus macaques. PLoS Pathog. 13, e1006537 (2017).

  50. 50.

    Biologic evidence required for Zika disease enhancement by dengue antibodies. Emerg. Infect. Dis. 23, 569–573 (2017).

  51. 51.

    , & Propagation, quantification, detection, and storage of West Nile virus. Curr. Protoc. Microbiol. 31, 15D.3.1–15D.3.18 (2013).

  52. 52.

    National Research Council. Guide for the Care and Use of Laboratory Animals 8th edn. (The National Academies Press, 2011).

  53. 53.

    et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg. Infect. Dis. 14, 1232–1239 (2008).

  54. 54.

    , , , & The aryl hydrocarbon receptor is important for proper seminiferous tubule architecture and sperm development in mice. Biol. Reprod. 90, 8 (2014).

  55. 55.

    , , , & Classification of mouse sperm motility patterns using an automated multiclass support vector machines model. Biol. Reprod. 84, 1207–1215 (2011).

Download references


We thank Haina Shin for advice on the intravaginal infection experiments, S. Whitehead (US National Institutes of Health (NIH)) for ZIKV-Brazil (Paraiba, 2015), S. Shresta(La Jolla Institute of Allergy and Immunology) for DENV-2 strain D2S20, P. Malasit and S. Noisakran (Mahidol University) for DENV-1, DENV-3, and DENV-4 isolates from patients, C. Simmons (University of Melbourne) for DENV-2 strain DF-699, A. Kohl, R.F. de Oliveira Freitas, and L.J. Pena (University of Glasgow) for ZIKV-Brazil PE243, and A. Sakuntabhai (Institut Pasteur) for ZIKV-Africa HD78788. Supported by grants and contracts from the NIH (R01 AI073755 (M.S.D.), R01 AI127828 (M.S.D.), R01 HD091218 (I.U.M. and M.S.D.), HHSN272201400018C (M.S.D.), T32 AI007163 (E.F.)), the Wellcome Trust (G.R.S.), MRC-NEWTON UK (J.M.), and the National Institute for Health Research Biomedical Research Centre funding scheme UK (G.R.S.).

Author information


  1. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.

    • Estefania Fernandez
    • , Indira U Mysorekar
    •  & Michael S Diamond
  2. Division of Immunology and Inflammation, Department of Medicine, Hammersmith Campus, Imperial College, London, UK.

    • Wanwisa Dejnirattisai
    • , Piyada Supasa
    • , Wiyada Wongwiwat
    • , Juthathip Mongkolsapaya
    •  & Gavin R Screaton
  3. Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri, USA.

    • Bin Cao
    • , Suzanne M Scheaffer
    • , Prabagaran Esakky
    • , Andrea Drury
    • , Kelle H Moley
    •  & Indira U Mysorekar
  4. Dengue Hemorrhagic Fever Research Unit, Office for Research and Development, Siriraj Hospital, Faculty of Medicine, Mahidol University, Bangkok, Thailand.

    • Juthathip Mongkolsapaya
  5. Medical Sciences Divisional Office, University of Oxford, John Radcliffe Hospital, Oxford, UK.

    • Gavin R Screaton
  6. Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.

    • Michael S Diamond
  7. Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.

    • Michael S Diamond
  8. Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, Missouri, USA.

    • Michael S Diamond


  1. Search for Estefania Fernandez in:

  2. Search for Wanwisa Dejnirattisai in:

  3. Search for Bin Cao in:

  4. Search for Suzanne M Scheaffer in:

  5. Search for Piyada Supasa in:

  6. Search for Wiyada Wongwiwat in:

  7. Search for Prabagaran Esakky in:

  8. Search for Andrea Drury in:

  9. Search for Juthathip Mongkolsapaya in:

  10. Search for Kelle H Moley in:

  11. Search for Indira U Mysorekar in:

  12. Search for Gavin R Screaton in:

  13. Search for Michael S Diamond in:


E.F., J.M., W.D., S.M.S., B.C., G.R.S., and M.S.D. designed the experiments; E.F., W.D., S.M.S., B.C., P.S., and W.W. performed the experiments; E.F., J.M., W.D., S.M.S., B.C., P.E., A.D., I.U.M., K.H.M., G.R.S., and M.S.D. analyzed the data; E.F. and M.S.D. wrote the first draft of the paper; and all authors participated in editing the final version of the manuscript.

Competing interests

M.S.D. is a consultant for Inbios, Visterra, Aviana and Sanofi-Pasteur and is on the Scientific Advisory Boards of Moderna and OvaGene. G.R.S. is on the Vaccine Scientific Advisory Board of GlaxoSmithKline plc.

Corresponding authors

Correspondence to Gavin R Screaton or Michael S Diamond.

Integrated supplementary information

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–4.

  2. 2.

    Life Sciences Reporting Summary

About this article

Publication history






Further reading